- Home
- EQS vs TXMD Comparison
EQS vs TXMD Comparison
Compare EQS & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EQS | TXMD |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 21.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EQS | TXMD |
|---|---|---|
| Price | $1.31 | $1.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.9K | ★ 85.5K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $1,377,000.00 | ★ $2,796,000.00 |
| Revenue This Year | N/A | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $78.18 |
| Revenue Growth | 21.11 | ★ 75.19 |
| 52 Week Low | $0.74 | $0.72 |
| 52 Week High | $2.49 | $2.15 |
Technical Indicators
Market Signals| Indicator | EQS | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 25.99 | 65.49 |
| Support Level | $1.27 | $1.58 |
| Resistance Level | $1.44 | $2.15 |
| Average True Range (ATR) | 0.13 | 0.17 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 9.32 | 74.91 |
Price Performance
Historical ComparisonAbout EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.